Trial Profile
Randomised Double Blind, Controlled, Parallel Group, Multicentre Study of a Subcutaneous Formulation of Icatibant Versus Oral Tranexamic Acid for the Treatment of Hereditary Angioedema (HAE).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jun 2021
Price :
$35
*
At a glance
- Drugs Icatibant (Primary) ; Tranexamic acid
- Indications Hereditary angioedema
- Focus Therapeutic Use
- Acronyms FAST-2
- Sponsors Jerini; Shire
- 12 Sep 2013 Results published in Allergy.
- 08 Apr 2009 New trial record.